CN103180342A - 用于治疗hiv的抗体 - Google Patents
用于治疗hiv的抗体 Download PDFInfo
- Publication number
- CN103180342A CN103180342A CN2011800520640A CN201180052064A CN103180342A CN 103180342 A CN103180342 A CN 103180342A CN 2011800520640 A CN2011800520640 A CN 2011800520640A CN 201180052064 A CN201180052064 A CN 201180052064A CN 103180342 A CN103180342 A CN 103180342A
- Authority
- CN
- China
- Prior art keywords
- antibody
- cdr
- hiv
- derivative
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/913,300 US9090686B2 (en) | 2009-04-29 | 2010-10-27 | Antibodies for the treatment of HIV |
US12/913,300 | 2010-10-27 | ||
PCT/EP2011/068905 WO2012055980A1 (en) | 2010-10-27 | 2011-10-27 | Antibodies for the treatment of hiv |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103180342A true CN103180342A (zh) | 2013-06-26 |
Family
ID=44913256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011800520640A Pending CN103180342A (zh) | 2010-10-27 | 2011-10-27 | 用于治疗hiv的抗体 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2632953A1 (ko) |
JP (1) | JP2014504147A (ko) |
KR (1) | KR20140009174A (ko) |
CN (1) | CN103180342A (ko) |
AU (1) | AU2011322508A1 (ko) |
CA (1) | CA2814908A1 (ko) |
MX (1) | MX2013004710A (ko) |
RU (1) | RU2013122770A (ko) |
WO (1) | WO2012055980A1 (ko) |
ZA (1) | ZA201302639B (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105980405A (zh) * | 2013-12-08 | 2016-09-28 | 派特塞尔有限公司 | Hiv抗原和抗体及其组合物、方法和用途 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014224049B2 (en) * | 2013-02-28 | 2018-11-29 | Therabiol, Inc. | HIV antigens and antibodies |
JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗pd-l1およびil-2サイトカイン |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2172485A1 (en) * | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
CN102459343A (zh) * | 2009-04-29 | 2012-05-16 | 皮埃尔法布雷医药公司 | 用于治疗hiv的抗cxcr4抗体 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US20050002939A1 (en) * | 2002-12-23 | 2005-01-06 | Albert Zlotnik | Tumor killing/tumor regression using CXCR4 antagonists |
MX2010012435A (es) * | 2008-05-14 | 2011-05-03 | Lilly Co Eli | Anticuerpos anti-cxcr4. |
JP2012158521A (ja) * | 2009-04-17 | 2012-08-23 | Kureha Corp | 外用剤 |
EP2371863A1 (en) * | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Humanized anti CXCR4 antibodies for the treatment of cancer |
-
2011
- 2011-10-27 CN CN2011800520640A patent/CN103180342A/zh active Pending
- 2011-10-27 JP JP2013535444A patent/JP2014504147A/ja active Pending
- 2011-10-27 MX MX2013004710A patent/MX2013004710A/es unknown
- 2011-10-27 RU RU2013122770/10A patent/RU2013122770A/ru not_active Application Discontinuation
- 2011-10-27 AU AU2011322508A patent/AU2011322508A1/en not_active Abandoned
- 2011-10-27 CA CA 2814908 patent/CA2814908A1/en not_active Abandoned
- 2011-10-27 KR KR20137011891A patent/KR20140009174A/ko not_active Application Discontinuation
- 2011-10-27 WO PCT/EP2011/068905 patent/WO2012055980A1/en active Application Filing
- 2011-10-27 EP EP11779612.8A patent/EP2632953A1/en not_active Withdrawn
-
2013
- 2013-04-12 ZA ZA2013/02639A patent/ZA201302639B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2172485A1 (en) * | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
CN102459343A (zh) * | 2009-04-29 | 2012-05-16 | 皮埃尔法布雷医药公司 | 用于治疗hiv的抗cxcr4抗体 |
Non-Patent Citations (2)
Title |
---|
STRIZKI J M ET AL: "A monoclonal antibody(12G5) directed against CXCR-4 inhibits infection with the dual-tropic human immunodeficiency virus type 1 isolate HIV-1(89.6) but not the T-tropic isolate HIV-1(HxB)", 《JOURNAL OF VIROLOGY》 * |
TANAKA R ET AL: "Unique monoclonal antibody recognizing the third extracellular loop of CXCR4 induces lymphocyte agglutination and enhances human immunodeficiency virus type 1-mediated syncytium formation and productive infection", 《JOURNAL OF VIROLOGY》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105980405A (zh) * | 2013-12-08 | 2016-09-28 | 派特塞尔有限公司 | Hiv抗原和抗体及其组合物、方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2012055980A1 (en) | 2012-05-03 |
EP2632953A1 (en) | 2013-09-04 |
KR20140009174A (ko) | 2014-01-22 |
CA2814908A1 (en) | 2012-05-03 |
MX2013004710A (es) | 2013-08-29 |
RU2013122770A (ru) | 2014-12-10 |
AU2011322508A1 (en) | 2013-05-02 |
ZA201302639B (en) | 2013-11-27 |
JP2014504147A (ja) | 2014-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102459343B (zh) | 用于治疗hiv的抗cxcr4抗体 | |
US11214616B2 (en) | Anti-TIGIT antibodies and their use as therapeutics and diagnostics | |
US10624974B2 (en) | Anti-OX40 antibody and application thereof | |
CN111788225A (zh) | 抗cd38抗体及与抗cd3和抗cd28抗体的组合 | |
JP2022550832A (ja) | Cd3を標的とする抗体、二重特異性抗体及びその使用 | |
BR112016005408B1 (pt) | Anticorpos anti-pd1, f(ab) ou f(ab)2 e uso referido anticorpo para tratamento de cancer ou infecção viral | |
KR20200037250A (ko) | 세포에 의해 발현되는 생물학적 활성을 조절하는 항체 | |
JP7145895B2 (ja) | 組換え二重特異性抗体 | |
CN103180342A (zh) | 用于治疗hiv的抗体 | |
TW202112826A (zh) | 抗tigit抗體及使用方法 | |
KR20230137948A (ko) | Cd19 및 cd22에 결합하는 이중특이적 키메라 항원 수용체 | |
JP2023546508A (ja) | 抗tigit抗体、その医薬組成物及び用途 | |
JP2019048804A (ja) | 抗pd−1抗体並びにその治療及び診断のための使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1182725 Country of ref document: HK |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130626 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1182725 Country of ref document: HK |